KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Operating Expenses: 2020-2024

Historic Other Operating Expenses for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2024 value amounting to $68.6 million.

  • Esperion Therapeutics' Other Operating Expenses rose 138.86% to $41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.0 million, marking a year-over-year increase of 133.36%. This contributed to the annual value of $68.6 million for FY2024, which is 58.55% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Other Operating Expenses of $68.6 million as of FY2024, which was up 58.55% from $43.3 million recorded in FY2023.
  • Esperion Therapeutics' Other Operating Expenses' 5-year high stood at $68.6 million during FY2024, with a 5-year trough of $2.4 million in FY2020.
  • Over the past 3 years, Esperion Therapeutics' median Other Operating Expenses value was $43.3 million (recorded in 2023), while the average stood at $46.3 million.
  • Data for Esperion Therapeutics' Other Operating Expenses shows a peak YoY soared of 494.36% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Other Operating Expenses stood at $2.4 million in 2020, then spiked by 494.36% to $14.2 million in 2021, then skyrocketed by 89.68% to $27.0 million in 2022, then surged by 60.44% to $43.3 million in 2023, then spiked by 58.55% to $68.6 million in 2024.